137 related articles for article (PubMed ID: 32024682)
1. A New Rho(d) Map to Diffuse Gastric Cancer.
Benton D; Chernoff J
Cancer Discov; 2020 Feb; 10(2):182-184. PubMed ID: 32024682
[TBL] [Abstract][Full Text] [Related]
2. Gain-of-Function
Zhang H; Schaefer A; Wang Y; Hodge RG; Blake DR; Diehl JN; Papageorge AG; Stachler MD; Liao J; Zhou J; Wu Z; Akarca FG; de Klerk LK; Derks S; Pierobon M; Hoadley KA; Wang TC; Church G; Wong KK; Petricoin EF; Cox AD; Lowy DR; Der CJ; Bass AJ
Cancer Discov; 2020 Feb; 10(2):288-305. PubMed ID: 31771969
[TBL] [Abstract][Full Text] [Related]
3. RHOA
Schaefer A; Hodge RG; Zhang H; Hobbs GA; Dilly J; Huynh MV; Goodwin CM; Zhang F; Diehl JN; Pierobon M; Baldelli E; Javaid S; Guthrie K; Rashid NU; Petricoin EF; Cox AD; Hahn WC; Aguirre AJ; Bass AJ; Der CJ
Sci Signal; 2023 Dec; 16(816):eadg5289. PubMed ID: 38113333
[TBL] [Abstract][Full Text] [Related]
4. Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers.
Cho SY; Park JW; Liu Y; Park YS; Kim JH; Yang H; Um H; Ko WR; Lee BI; Kwon SY; Ryu SW; Kwon CH; Park DY; Lee JH; Lee SI; Song KS; Hur H; Han SU; Chang H; Kim SJ; Kim BS; Yook JH; Yoo MW; Kim BS; Lee IS; Kook MC; Thiessen N; He A; Stewart C; Dunford A; Kim J; Shih J; Saksena G; Cherniack AD; Schumacher S; Weiner AT; Rosenberg M; Getz G; Yang EG; Ryu MH; Bass AJ; Kim HK
Gastroenterology; 2017 Aug; 153(2):536-549.e26. PubMed ID: 28522256
[TBL] [Abstract][Full Text] [Related]
5. Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer.
Shimada S; Mimata A; Sekine M; Mogushi K; Akiyama Y; Fukamachi H; Jonkers J; Tanaka H; Eishi Y; Yuasa Y
Gut; 2012 Mar; 61(3):344-53. PubMed ID: 21865403
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management.
Suriano G; Yew S; Ferreira P; Senz J; Kaurah P; Ford JM; Longacre TA; Norton JA; Chun N; Young S; Oliveira MJ; Macgillivray B; Rao A; Sears D; Jackson CE; Boyd J; Yee C; Deters C; Pai GS; Hammond LS; McGivern BJ; Medgyesy D; Sartz D; Arun B; Oelschlager BK; Upton MP; Neufeld-Kaiser W; Silva OE; Donenberg TR; Kooby DA; Sharma S; Jonsson BA; Gronberg H; Gallinger S; Seruca R; Lynch H; Huntsman DG
Clin Cancer Res; 2005 Aug; 11(15):5401-9. PubMed ID: 16061854
[TBL] [Abstract][Full Text] [Related]
7. In vivo effects of mutant RHOA on tumor formation in an orthotopic inoculation model.
Nishizawa T; Nakano K; Fujii E; Komura D; Kuroiwa Y; Ishimaru C; Monnai M; Aburatani H; Ishikawa S; Suzuki M
Oncol Rep; 2019 Nov; 42(5):1745-1754. PubMed ID: 31485674
[TBL] [Abstract][Full Text] [Related]
8. RHOA drivers take alternate routes in gastric cancer.
Benton D; Chernoff J
Sci Signal; 2023 Dec; 16(816):eadk9171. PubMed ID: 38113334
[TBL] [Abstract][Full Text] [Related]
9. CDH1 somatic alterations in Mexican patients with diffuse and mixed sporadic gastric cancer.
Bustos-Carpinteyro AR; Oliveira C; Sousa A; Oliveira P; Pinheiro H; Carvalho J; Magaña-Torres MT; Flores-Miramontes MG; Aguilar-Lemarroy A; Jave-Suárez LF; Peregrina-Sandoval J; Cruz-Ramos JA; Sánchez-López JY
BMC Cancer; 2019 Jan; 19(1):69. PubMed ID: 30642281
[TBL] [Abstract][Full Text] [Related]
10. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria.
Brooks-Wilson AR; Kaurah P; Suriano G; Leach S; Senz J; Grehan N; Butterfield YS; Jeyes J; Schinas J; Bacani J; Kelsey M; Ferreira P; MacGillivray B; MacLeod P; Micek M; Ford J; Foulkes W; Australie K; Greenberg C; LaPointe M; Gilpin C; Nikkel S; Gilchrist D; Hughes R; Jackson CE; Monaghan KG; Oliveira MJ; Seruca R; Gallinger S; Caldas C; Huntsman D
J Med Genet; 2004 Jul; 41(7):508-17. PubMed ID: 15235021
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1.
van der Post RS; Vogelaar IP; Manders P; van der Kolk LE; Cats A; van Hest LP; Sijmons R; Aalfs CM; Ausems MG; Gómez García EB; Wagner A; Hes FJ; Arts N; Mensenkamp AR; van Krieken JH; Hoogerbrugge N; Ligtenberg MJ
Gastroenterology; 2015 Oct; 149(4):897-906.e19. PubMed ID: 26072394
[TBL] [Abstract][Full Text] [Related]
12. Aberrant alternative splicing of RHOA is associated with loss of its expression and activity in diffuse-type gastric carcinoma cells.
Miyamoto S; Nagamura Y; Nakabo A; Okabe A; Yanagihara K; Fukami K; Sakai R; Yamaguchi H
Biochem Biophys Res Commun; 2018 Jan; 495(2):1942-1947. PubMed ID: 29247652
[TBL] [Abstract][Full Text] [Related]
13. Multi-omics analysis identifies pathways and genes involved in diffuse-type gastric carcinogenesis induced by E-cadherin, p53, and Smad4 loss in mice.
Park JW; Kim MS; Voon DC; Kim SJ; Bae J; Mun DG; Ko SI; Kim HK; Lee SW; Kim DY
Mol Carcinog; 2018 Jul; 57(7):947-954. PubMed ID: 29528141
[TBL] [Abstract][Full Text] [Related]
14. E-cadherin is a biomarker for ferroptosis sensitivity in diffuse gastric cancer.
Minikes AM; Song Y; Feng Y; Yoon C; Yoon SS; Jiang X
Oncogene; 2023 Mar; 42(11):848-857. PubMed ID: 36717701
[TBL] [Abstract][Full Text] [Related]
15. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma.
Kakiuchi M; Nishizawa T; Ueda H; Gotoh K; Tanaka A; Hayashi A; Yamamoto S; Tatsuno K; Katoh H; Watanabe Y; Ichimura T; Ushiku T; Funahashi S; Tateishi K; Wada I; Shimizu N; Nomura S; Koike K; Seto Y; Fukayama M; Aburatani H; Ishikawa S
Nat Genet; 2014 Jun; 46(6):583-7. PubMed ID: 24816255
[TBL] [Abstract][Full Text] [Related]
16. Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer.
Humar B; Fukuzawa R; Blair V; Dunbier A; More H; Charlton A; Yang HK; Kim WH; Reeve AE; Martin I; Guilford P
Cancer Res; 2007 Mar; 67(6):2480-9. PubMed ID: 17363565
[TBL] [Abstract][Full Text] [Related]
17. Recurrent RhoGAP gene fusion CLDN18-ARHGAP26 promotes RHOA activation and focal adhesion kinase and YAP-TEAD signalling in diffuse gastric cancer.
Zhang F; Sahu V; Peng K; Wang Y; Li T; Bala P; Aitymbayev D; Sahgal P; Schaefer A; Der CJ; Ryeom S; Yoon S; Sethi N; Bass AJ; Zhang H
Gut; 2024 Apr; ():. PubMed ID: 38621923
[TBL] [Abstract][Full Text] [Related]
18. Predicting the Functional Impact of CDH1 Missense Mutations in Hereditary Diffuse Gastric Cancer.
Melo S; Figueiredo J; Fernandes MS; Gonçalves M; Morais-de-Sá E; Sanches JM; Seruca R
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29231860
[TBL] [Abstract][Full Text] [Related]
19. CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study.
Benusiglio PR; Malka D; Rouleau E; De Pauw A; Buecher B; Noguès C; Fourme E; Colas C; Coulet F; Warcoin M; Grandjouan S; Sezeur A; Laurent-Puig P; Molière D; Tlemsani C; Di Maria M; Byrde V; Delaloge S; Blayau M; Caron O
J Med Genet; 2013 Jul; 50(7):486-9. PubMed ID: 23709761
[TBL] [Abstract][Full Text] [Related]
20. RAS and RHO family GTPase mutations in cancer: twin sons of different mothers?
Hodge RG; Schaefer A; Howard SV; Der CJ
Crit Rev Biochem Mol Biol; 2020 Aug; 55(4):386-407. PubMed ID: 32838579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
